Morphine in slow-release tablets

Slow-release tablets containing 10 mg morphine sulphate (MST-1 Continus - Napp) have recently been introduced for the long-term management of patients with severe and intractable pain. Morphine is the analgesic of choice for severe pain in cancer,1 but when given by mouth as an aqueous solution it needs to be taken every 4 hours. This solution is convenient for most patients, but those who are forgetful, live alone or have poor eyesight may find their therapy difficult to manage. The aim of a slow-release formulation of morphine is to allow a reduction in the frequency of analgesic administration, and given at bedtime it may also help patients who would otherwise wake in pain in the early morning.

Download Full-text

DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS

Neuro-Oncology ◽

10.1093/neuonc/noaa222.038 ◽

2020 ◽

Vol 22 (Supplement_3) ◽

pp. iii284-iii284

Author(s):

Natalia Stepien ◽

Andreas Peyrl ◽

Amedeo Azizi ◽

Johannes Gojo ◽

Lisa Mayr ◽

...

Keyword(s):

Brain Tumors ◽

Tumor Cells ◽

Slow Release ◽

Intrathecal Therapy ◽

Liposomal Cytarabine ◽

Release Formulation ◽

Malignant Brain Tumors ◽

Slow Release Formulation ◽

Anti Cancer

Abstract BACKGROUND Malignant brain tumors of childhood carry a high risk for leptomeningeal dissemination and tumor cells floating in the CSF are often not amenable to systemic and/or antiangiogenic chemotherapy. We report on our experience with an intraventricular therapy consisting of alternating cycles of liposomal cytarabine and etoposide. PATIENTS AND METHODS Between 2004 and 2017, 75 patients aged 0.6 to 22 years (median 11) with various malignant brain tumors received intraventricular etoposide 0.25mg (<1year) - 0.5mg on five consecutive days alternating with liposomal cytarabine at a dose of 25mg (<3 years) - 50mg via an Ommaya reservoir. RESULTS 5533 doses of etoposide (5–277/patient, median 141) corresponding to 1–56 five-day-cycles/patient alternating with 534 doses of liposomal cytarabine (1–21/patient, median 11) were administered. Treatment was given over a period of 1 – 146 months (median 73.5). Toxicities did occur but were infrequent and mostly mild. Since all patients received some sort of concurrent anti-cancer therapy, the efficacy of intrathecal therapy cannot be assessed independently. However, 29/75 patients are still alive, and none of the patients had tumor cells in the CSF at their last evaluation. CONCLUSION In conclusion, alternating intraventricular liposomal cytarabine and etoposide produced responses and proved to be an important adjunct for patients receiving drugs with a low penetrance into the CSF. Since production of liposomal cytarabine was discontinued in 2017 it remains to be determined whether substitution of the slow release formulation by aqueous cytarabine on days 1, 4, 8, and 11 may produce similar results.

Download Full-text

Mesalazine (5-aminosalicylic acid) induced chronic hepatitis

Gut ◽

10.1136/gut.44.6.886 ◽

1999 ◽

Vol 44 (6) ◽

pp. 886-888 ◽

Cited By ~ 40

Author(s):

P Deltenre ◽

A Berson ◽

P Marcellin ◽

C Degott ◽

M Biour ◽

...

Keyword(s):

Chronic Hepatitis ◽

Side Effects ◽

Adverse Effects ◽

Liver Dysfunction ◽

Liver Enzymes ◽

Slow Release ◽

Aminosalicylic Acid ◽

Safe Alternative ◽

Release Formulation ◽

Slow Release Formulation

BACKGROUNDTreatment of ulcerative colitis or Crohn’s disease with sulphasalazine causes several adverse effects, including hepatitis. Sulphasalazine is cleaved by colonic bacteria into 5-aminosalicylic acid and sulphapyridine. Received wisdom was that 5-aminosalicylic acid was topically active, whereas sulphapyridine was absorbed and caused immunoallergic side effects. Mesalazine, a slow release formulation of 5-aminosalicylic acid, was expected to be a safe alternative. However, several cases of acute hepatitis have been reported.CASE REPORTA 65 year old man had increased liver enzymes, anti-nuclear and anti-smooth muscle autoantibodies and IgG levels, and lesions of chronic hepatitis after 21 months of mesalazine treatment. Although liver dysfunction had been identified eight months earlier, simvastatin rather than mesalazine had been withdrawn, without any improvement. In contrast, liver enzyme and IgG levels became normal and autoantibodies disappeared after discontinuation of mesalazine administration.CONCLUSIONContrary to initial expectations, mesalazine can cause most of the sulphasalazine induced adverse effects, and hepatic side effects may be almost as frequent. When liver dysfunction occurs, mesalazine administration should be discontinued to avoid the development of chronic hepatitis and liver fibrosis.

Download Full-text

Pharmacokinetics of a Slow-Release Formulation of Soybean Isoflavones in Healthy Postmenopausal Women

Journal of Agricultural and Food Chemistry ◽

10.1021/jf0488099 ◽

2005 ◽

Vol 53 (6) ◽

pp. 1938-1944 ◽

Cited By ~ 22

Author(s):

Kenneth D. R. Setchell ◽

Amnon Brzezinski ◽

Nadine M. Brown ◽

Pankaj B. Desai ◽

Murad Melhem ◽

...

Keyword(s):

Postmenopausal Women ◽

Slow Release ◽

Release Formulation ◽

Soybean Isoflavones ◽

Slow Release Formulation

Download Full-text

Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus andper os slow-release formulation

Digestive Diseases and Sciences ◽

10.1007/bf01296618 ◽

1991 ◽

Vol 36 (12) ◽

pp. 1735-1740 ◽

Cited By ~ 22

Author(s):

S. Bondesen ◽

J. Hegnh�j ◽

F. Larsen ◽

S. Honor� Hansen ◽

C. P. Hansen ◽

...

Keyword(s):

Slow Release ◽

Intravenous Bolus ◽

Aminosalicylic Acid ◽

Release Formulation ◽

Slow Release Formulation

Download Full-text

slow release formulation (SR)

Dictionary of Pharmaceutical Medicine ◽

10.1007/978-3-211-89836-9_1300 ◽

2009 ◽

pp. 170-170

Author(s):

Gerhard Nahler

Keyword(s):

Slow Release ◽

Release Formulation ◽

Slow Release Formulation

Download Full-text

Development and Laboratory Evaluation of a Slow Release Formulation of Fipronil against Subterranean Termites (Odontotermes obesus Rambur)

Sarhad Journal of Agriculture ◽

10.17582/journal.sja/2020/36.4.1279.1288 ◽

2020 ◽

Vol 36 (4) ◽

Author(s):

Sajid Amin Sarmad ◽

Muhammad Zeeshan Majeed ◽

Muhammad Luqman ◽

Muhammad Asam Riaz ◽

Sohail Ahmed ◽

...

Keyword(s):

Slow Release ◽

Laboratory Evaluation ◽

Subterranean Termites ◽

Release Formulation ◽

Slow Release Formulation ◽

Odontotermes Obesus

Download Full-text

Depronal SA: sustained-action dextropropoxyphene

Drug and Therapeutics Bulletin ◽

10.1136/dtb.10.10.40 ◽

1972 ◽

Vol 10 (10) ◽

pp. 40-40

Keyword(s):

Analgesic Effect ◽

Slow Release ◽

Narcotic Drug ◽

Release Formulation ◽

Slow Release Formulation ◽

Sustained Action

Depronal SA is a slow-release formulation of dextropropoxyphene,1 a synthetic non-narcotic drug with about the same analgesic effect as codeine. The drug is available alone as 65 mg capsules (Doloxene) and also mixed with various other drugs, e.g. as Doloxene Co-65 (with aspirin, phenacetin and caffeine) and as Distalgesic (with paracetamol).

Download Full-text